You quoted the member at $299. The invoice landed at $214 in drug COGS plus fees you never saw in the demo. That is the margin trap cash-pay clinic ops teams describe when they ask whether catalog numbers are pass-through cost or platform markup baked into the vial line.
This guide defines pass-through 503A pricing for clinic buyers, contrasts it with markup portals, and shows where landed cost fits before you quote patients or pick a 503A partner.
Who this is for
This article is for cash-pay clinic founders, ops leads, pharmacy coordinators, and telehealth finance owners who prescribe through 503A compounders and set member pricing from clinic COGS.
You are not the audience if you are a patient comparing tirzepatide membership prices or hunting retail coupons. Consumer comparison sites solve a different problem. This is coordinator-side B2B economics only. It is not medical advice.
What is pass-through 503A pricing for cash-pay clinics?
Pass-through 503A pricing means the clinic sees the real landed cost from the compounding pharmacy on each medication line, without intermediary markup baked into the vial price.
For cash-pay clinics and telehealth brands, that model has four pillars:
| Pillar | What it means for clinic ops | Why it matters |
|---|---|---|
| VISIBLE | Per-vial pass-through drug cost appears in catalog, on every cart line, and in checkout before card authorization | You quote from screen numbers, not post-order spreadsheets |
| NO MARKUP | Drug cost reflects compounder pricing; platform charges sit on a separate facilitation row | Margin stays with the clinic instead of a 40 to 80 percent hidden layer |
| QUOTE READY | Landed COGS is settled before the member pays out of pocket | Membership tiers defend real economics, not padded guesses |
| COMPARE | Guest catalog access lets ops pull top SKUs without a sales call | You see the delta against legacy portal pricing in minutes |
Pass-through is not a discount promise. It is a disclosure model. The clinic still pays facilitation, processing, and shipping. The difference is whether those economics are visible on separate rows or buried inside a padded medication line.
Pass-through pricing vs markup portals
Most clinic ordering platforms fall into one of two economic models. Clinic ops should know which one they are on before they build a comparison chart.
| Dimension | Pass-through 503A pricing | Markup portal pricing |
|---|---|---|
| Medication line | Shows compounder cost at stated strength and supply duration | Often includes 40 to 80 percent intermediary margin |
| Platform fee | Disclosed facilitation fee separate from drug cost | Bundled inside vial price or revealed only at checkout |
| Catalog to checkout | Same per-vial drug cost from browse to authorization | Bait-and-switch adjustments common on payment screen |
| Member quoting | Quote from catalog and cart numbers before submit | Quote from faith; reconcile margin after invoice |
| Partner comparison | Drug rows align with compounder economics | You rank markup layers, not 503A partners |
Markup portals are not dishonest by default. Many charge a facilitation layer and call the vial price “base cost.” The ops failure happens when no separate row exists and coordinators treat inflated drug COGS as pass-through compounder pricing.
If your rep cannot answer whether catalog price is medication only or all-in, you are not on pass-through economics yet.
How pass-through pricing fits the cash-pay clinic workflow
Cash-pay clinics and telehealth brands live on margin between landed COGS and member pricing. Pass-through economics should show up at four workflow steps:
1. Browse formulary before you onboard
Open the medication catalog and search by drug name or stable SKU. Every strength should show resolved per-vial pass-through cost so you can compare semaglutide, testosterone, and peptide lines you order every week. See the medication catalog pattern: cost on the row while you browse, not after signup.
2. Build the clinic cart with cost on every line
When coordinators add a patient line, the cart should carry the same per-vial price from catalog. No surprise adjustment when lines stack up for refill day. Batch workflows in one cart checkout only save time when economics stay visible on each row.
3. Checkout with a full fee breakdown
Checkout should separate pass-through drug cost from disclosed facilitation, then add partner processing and shipping assumptions before card authorization. That is the screen your worksheet should match. Clinic checkout proof is fee rows on the totals panel, not a single opaque number.
4. Quote members from settled landed cost
Member pricing should come from landed cost per patient-period at the titration step and supply duration you actually prescribe, plus program fees on top. Pass-through drug cost is row one; landed cost adds facilitation, processing, and shipping. For GLP-1-heavy clinics, run that sequence in how to quote GLP-1 patients with real per-vial cost before you reset tiers.
Tie pass-through pricing to landed cost and partner comparison
Pass-through drug cost is the foundation row inside landed cost. It is not the whole story.
Landed cost per vial includes base compounded medication price plus facilitation, processing, shipping, and any disclosed platform charges required to place and receive that vial at a stated strength and approximate days of supply. Clinic ops sum those rows before they quote members or rank 503A partners.
When fee lines hide until checkout, pass-through economics break even if the drug row looks clean. Read hidden shipping and processing fees in compound pharmacy quotes for the fee table ops should require upfront.
When partners quote different supply durations on separate rows, pass-through vial price is not comparable until you normalize days of supply. See month vs two-month compound supply pricing and compare 503A pricing apples to apples.
When you juggle three partner PDFs with different labels, use how clinics compare prescription prices across 503A partners. The pass-through row is the same; the workflow keeps columns aligned.
Build every comparison on the five rows every chart needs: product definition, supply duration, base medication price, checkout fees, and estimated landed cost.
Still asking whether compounding is cheaper at all? The clinic-side answer is landed cost per patient-period, not headline vial price. See are compounding pharmacies cheaper for clinics.
For high-volume semaglutide lines, define all-in vial COGS in landed cost per vial before quoting semaglutide before you touch membership pricing.
Five mistakes clinics make with 503A pricing models
1. Treating catalog teaser price as pass-through COGS.
If facilitation is bundled or processing ships on a different screen, you are not quoting from landed cost.
2. Quoting members before fee rows reconcile.
Base medication price is not landed cost. Row 3 is not row 5.
3. Comparing pass-through cost to a markup portal vial line.
You are ranking different economic models. Ask both vendors for drug cost and facilitation on separate rows.
4. Skipping supply duration on the same row as price.
A lower per-vial pass-through quote on a 14-day supply can cost more per month than a higher quote on 28 days.
5. Picking a portal before you can see top SKUs.
Guest catalog compare on the lines you order every week beats a demo slide with three cherry-picked prices.
Where Fizy Health fits (honest framing)
Fizy Health is an ordering layer for clinics that already use 503A compounders. We are not a compounder. We do not replace your pharmacy partners. We make pass-through economics visible before checkout so your worksheet matches what coordinators see on screen.
Pass-through pricing shows resolved per-vial 503A drug cost in the medication catalog and on every line in one cart checkout. The medication price is not padded with opaque platform markup.
Clinic checkout separates pass-through drug cost from a disclosed facilitation fee on the totals panel before card authorization. Processing and shipping assumptions still come from your 503A partners and ship-to destinations; the platform fee is not hidden inside the vial line.
That is the proof behind the outcome field teams name: landed cost you can compare and quote confidently, with drug cost and platform fees on separate rows before anyone pays.
Fizy Health charges a disclosed facilitation fee per order instead of baking 40 to 80 percent markup into medication lines. Platform fee structure lives on the pricing page. Telehealth-specific workflow context is on the telehealth ops page. Weight-loss and GLP-1 margin context is on the weight-loss ops page.
We will not promise you a fixed margin uplift. Economics depend on your current portal, formulary, volume, and fee stack. Pass-through pricing gives you visible COGS so your team can run the comparison math honestly.
Bottom line
Pass-through 503A pricing for cash-pay clinics means real compounder cost on the medication row, platform fees disclosed separately, and landed economics visible before checkout.
Markup portals hide margin inside the vial price. Pass-through portals show it on separate rows so coordinators quote members from numbers they can defend.
Build your comparison chart on landed cost, not headline vial price. Require fee disclosure upfront. Quote patients only after catalog, cart, and checkout totals reconcile on the same worksheet.
The foundational question is not whether compounding is cheap. It is whether you can see what you actually pay the 503A partner before the member pays you.